TIL - NASDAQ

Instil Bio, Inc.

Instil Bio, Inc.

TILยทNASDAQ

$8.10

-0.84%
HealthcareBiotechnology

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$54.94M
EPS-10.7000
P/E Ratio-0.76
Earnings Date08/07/2026
Instil Bio, Inc.

Instil Bio, Inc. Fair Value Envelope

TIL ยท NASDAQ

Our analysis suggests that TIL has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $8.1013, this represents a potential HIDDEN relative to our calculated worth for Instil Bio, Inc..

HIDDEN
Intrinsic Value
Current Price: $8.1013

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$2.5B
+ Cash & Equivalents$6.6M
Firm Value-$2.5B
- Debt$85.2M
Equity Value-$2.6B
/ Shares Outstanding6,750,698B
DCF Value-$380
OVERVALUED BY 4794%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$52.8M
-$76.2M
-$109.9M
-$158.6M
-$228.8M
-$330.1M
-$476.1M
-$686.9M
-$990.9M
-$1.4B
Maintenance CapEx
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
Owner Earnings
-$52.8M
-$76.2M
-$109.9M
-$158.6M
-$228.8M
-$330.1M
-$476.1M
-$686.9M
-$990.9M
-$1.4B
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$48.9M
-$65.3M
-$87.3M
-$116.6M
-$155.7M
-$208.0M
-$277.8M
-$371.1M
-$495.7M
-$662.1M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your TIL research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.